Medilabo

Executive Summary

Medilabo RFP is a preclinical-stage Japanese biopharmaceutical company developing a proprietary intranasal drug delivery platform to treat central nervous system disorders, particularly Alzheimer's disease and frontotemporal dementia. By targeting the olfactory nerve, the technology bypasses the blood-brain barrier, enabling direct delivery of repurposed small molecules such as rifampicin and resveratrol. Founded in 2020 and based in Kyoto, the company has raised $290 million to advance its pipeline. Medilabo's approach addresses a critical unmet need in neurodegenerative disease treatment, where existing therapies are limited by poor brain penetration. The company's focus on repurposed compounds may accelerate development timelines and reduce risk, though it remains in preclinical stages with no disclosed regulatory filings. With strong financial backing and a novel delivery mechanism, Medilabo is positioned as an innovative player in the CNS drug delivery space.

Upcoming Catalysts (preview)

• Q3 2026Completion of preclinical safety/toxicology studies and potential IND-enabling filing60% success
• Q2 2026Publication of preclinical efficacy data for Alzheimer's disease candidate in peer-reviewed journal70% success
• Q1 2027Strategic partnership or licensing deal for intranasal delivery platform with major pharma50% success